索拉非尼洗脱微球的制备与验证:在大鼠肝细胞癌模型中增强经导管动脉化疗栓塞疗效
本研究制备了载索拉非尼的聚乳酸-羟基乙酸共聚物微球(SOR-EMs),并在大鼠原位肝细胞癌模型中验证其联合经导管动脉化疗栓塞(TACE)的疗效。SOR-EMs平均粒径6.6 μm±2.3,索拉非尼载药效率53.7%±8.3,具备T2加权MRI显像能力。DLE+SOR-EM组较单用DLE组显示更强的肿瘤生长抑制效果(P<.05),且CD34阳性微血管面积百分比最低(所有比较P<.01)。
要点
- SOR-EMs平均粒径6.6 μm±2.3,载药效率53.7%±8.3,可用MRI监测。
- DLE+SOR-EM组肿瘤生长抑制效果优于单用DLE组(P<.05)。
- DLE+SOR-EM组CD34阳性微血管面积百分比低于其他治疗组(P<.01)。
关键影像表现/征象
- SOR-EMs平均粒径6.6 μm±2.3,索拉非尼载药效率53.7%±8.3,具备T2加权MRI显像能力。
- 经动脉注射的SOR-EMs可通过MRI成功监测。
- DLE+SOR-EM组肿瘤生长抑制效果优于单用DLE组(P<.05)。
- DLE+SOR-EM组CD34阳性染色面积百分比低于其他治疗组(所有比较P<.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To validate the therapeutic efficacy of sorafenib-eluting embolic microspheres (SOR-EMs) used in combination with transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC) in a preclinical animal model.
MATERIALS AND METHODS: SOR-EMs were prepared with poly(d,l-lactide-co-glycolide), iron oxide nanoparticles, and sorafenib. The morphology of the prepared SOR-EMs was confirmed by using optical microscopy. Drug release from the SOR-EMs was quantified in vitro by using high-performance liquid chromatography. In an orthotopic rat model of HCC, embolic doxorubicin-Lipiodol (ethiodized oil) emulsion (DLE) and SOR-EMs were sequentially injected into the hepatic artery of the rats: The rats in group 1 were injected with DLE; group 2 was injected with DLE plus unloaded embolic microspheres (DLE + EM); group 3, with DLE plus SOR-EMs (DLE + SOR-EM); and group 4, with saline solution. The SOR-EM and tumor size changes in each group (of six rats each) over time were measured by using MRI. Tissues were assessed by using immunohistochemistry, with hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated dUTP (2'-deoxyuridine 5'-triphosphate) nick-end labeling staining used for dead cells and CD34 staining used for new microvessel formation.
RESULTS: The SOR-EMs were a mean size of 6.6 μm ± 2.3 (standard deviation) and showed 53.7% ± 8.3 sorafenib loading efficiency with T2-weighted MRI capability. In the HCC rat model, the intra-arterially injected SOR-EMs were successfully monitored by using MRI. The DLE + SOR-EM-treated rats showed a superior tumor growth-inhibitory effect compared with the rats treated with DLE only (P < .05). Immunohistochemical assessment of tissue specimens showed that compared with the other treatment groups, the DLE + SOR-EM treatment group had the lowest number of microvessels, as quantified by using the percentage of CD34-positive stained area (P < .01 for all comparisons).
CONCLUSION: In a preclinical rat HCC model, SOR-EMs used in combination with DLE TACE were effective in treating HCC.Keywords: Chemoembolization, Experimental Investigations, Laboratory Tests, Liver, Technology Assessment Supplemental material is available for this article. © RSNA, 2021See also the commentary by Yamada and Gayed in this issue.
引用
- Park W, Cho S, Ji J, et al. Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma. Radiol Imaging Cancer. 2021. PMID: 33575658. doi:10.1148/rycan.2021200006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。